Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (141-150 of 383) with videos related to

Pageof 39
Sort By:
Haematologica|October 8, 2013
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classificationMeir Wetzler, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaOphelia Q P Yin, Frank J Giles, Michele Baccarani, et al.
Lancet (London, England)|February 21, 2004
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemiaAdolfo A Ferrando, Donna S Neuberg, Richard K Dodge, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Journal of Oncology Practice|November 14, 2018
Treatment of Acute Promyelocytic Leukemia in AdultsAfaf E G Osman, Jennifer Anderson, Jane E Churpek, et al.
Leukemia & Lymphoma|March 11, 2017
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemiaNiloufer Khan, Andrew Hantel, Randall W Knoebel, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
Experimental Hematology & Oncology|January 19, 2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemiaHongtao Liu, Yuanyuan Zha, Noura Choudhury, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Pageof 39

Showing results (141-150 of 383) with videos related to

Sort By:
Pageof 39
Haematologica|October 8, 2013
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classificationMeir Wetzler, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaOphelia Q P Yin, Frank J Giles, Michele Baccarani, et al.
Lancet (London, England)|February 21, 2004
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemiaAdolfo A Ferrando, Donna S Neuberg, Richard K Dodge, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Journal of Oncology Practice|November 14, 2018
Treatment of Acute Promyelocytic Leukemia in AdultsAfaf E G Osman, Jennifer Anderson, Jane E Churpek, et al.
Leukemia & Lymphoma|March 11, 2017
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemiaNiloufer Khan, Andrew Hantel, Randall W Knoebel, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
Experimental Hematology & Oncology|January 19, 2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemiaHongtao Liu, Yuanyuan Zha, Noura Choudhury, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Pageof 39